Athenex (NASDAQ: ATNX)
Some price data may be temporarily unavailable.
Athenex Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Athenex Company Info
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
News & Analysis
Why Shares of Ziopharm Oncology Jumped on Wednesday
The company hopes to develop cancer treatments that work via individualized gene therapy and has two promising pipeline candidates.
Why Athenex Stock Skyrocketed Today
A blockbuster acquisition could help the biotech "convert cancer into a chronic disease."
Investing $5,000 in These 2 Biotechs Could Make You Rich
These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.
Why Athenex Stock Is Down Today
The company announced the pricing of a public offering of common stock.
Why Athenex Stock Is Up Today
The company announced good news regarding one of its leading pipeline candidates.
Here's Why Athenex Stock Is Sliding Today
Investors did not see the clinical trial results they wanted.
Biotech’s Year-End To-Do List
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
2 Breast Cancer Fighting Stocks to Invest In
Promising new results in breast cancer will be presented at next week's San Antonio Breast Cancer Symposium. Here's what to look for.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.